

## Aratana Therapeutics, Inc. Announces Proposed Public Offering

Written by Australian Business

---

KANSAS CITY, Kan., Jan. 22, 2014 /PRNewswire/ -- **Aratana Therapeutics, Inc.** (NASDAQ: [PETX](#))

), a pet therapeutics company focused on the licensing or acquisition, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that it is commencing an underwritten registered public offering of 5,500,000 shares of its common stock. A total of 4,500,000 shares are being offered by Aratana Therapeutics, and a total of 1,000,000 shares are being offered by certain selling stockholders. A selling stockholder also intends to grant the underwriters a 30-day option to purchase up to a maximum of 825,000 additional shares of common stock.

Jefferies LLC, Barclays, and William Blair will act as joint book-running managers for the offering. JMP Securities and Craig-Hallum Capital Group will act as co-managers.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus. Copies of the preliminary prospectus

## Aratana Therapeutics, Inc. Announces Proposed Public Offering

Written by Australian Business

---

related to the offering may be obtained, when available, from Jefferies LLC, c/o Equity Syndicate Prospectus Department, 520 Madison Avenue, 12<sup>th</sup> FL, New York, NY 10022, [Prospectus\\_Department@Jefferies.com](mailto:Prospectus_Department@Jefferies.com), (877) 547-6340; or Barclays, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, [barclaysprospectus@broadridge.com](mailto:barclaysprospectus@broadridge.com), (888) 603-5847; or William Blair, Attention: Prospectus Department, 222 West Adams Street, Chicago, IL 60606, [prospectus@williamblair.com](mailto:prospectus@williamblair.com), telephone: (800) 621-0687.

**Contacts:** [Tiberend Strategic Advisors, Inc.](#)

Joshua Drumm, Ph.D. [jdrumm@tiberend.com](mailto:jdrumm@tiberend.com) ; (212) 375-2664

Andrew Mielach [amielach@tiberend.com](mailto:amielach@tiberend.com) ; (212) 375-2694

SOURCE Aratana Therapeutics, Inc.